(Date:11/19/2009)...maize, also known as corn, researchers across the ...ld pave the way to significant improvements in a p...feed and fiber around the world. , The new map, ...p, charts genetic diversity and recombination acro...earch team, led by U.S. Department of Agriculture ...
(Date:11/19/2009)...entists have helped identify and group the genes t... in maize, an effort that expands their ability to...for biofuels production. , The Purdue scientists...ll biology, published their findings on the 750 ce... Thursday (Nov. 19). They also were co-authors on ...
(Date:11/19/2009)... developed by researchers at the University of Ill...fic gene-regulatory regions without requiring prio... The technique has been experimentally validated i..., "Our statistical approach is more widely applic...ul for investigating gene regulatory networks with...
Breaking Biology News(10 mins):Maize cell wall genes identified, giving boost to biofuel research 2Technique finds gene regulatory sites without knowledge of regulators 2Study explains potential failure of oral contraceptives with obese women 9265 1Study explains potential failure of oral contraceptives with obese women 9265 2Study explains potential failure of oral contraceptives with obese women 9265 3 2420 million NIH grant to transform clinical research at UIC 9263 1 2420 million NIH grant to transform clinical research at UIC 9263 2Sysmex America Receives Highest Vendor Designation from MedAssets Supply Chain Systems 51679 1Sysmex America Receives Highest Vendor Designation from MedAssets Supply Chain Systems 51679 2(Date:11/19/2009)...PRNewswire-FirstCall/ -- Omeros Corporation (Nasda...ults for the third quarter ended September 30, 200...Omeros reported a net loss of $3.9 million, or $1....llion, or $2.54 per share, for the same period in ..., the Company reported a net loss of $15.5 million...
(Date:11/19/2009)... NeoStem, Inc. (NYSE Amex...lowing letter to its shareholders, discussing the ...na Biopharmaceuticals Holdings, Inc. (CHBP), an in...eople,s Republic of China. The merger gives NeoSte...ceutical Co. Ltd., CHBP,s primary operating subsid...
(Date:11/19/2009)...rmany, November 19 MONITORING FORC...16th, 2009 Flibanserin in the,indication treatment...,s,disease for orphan drug status designation with...duced dyskinesia is a complication of the mainstay...urden to some of those,affected, since it may be d...
(Date:11/19/2009)...ld,s Top Gene Synthesis Companies Form Internation...Best Practices in Risk Reduction ,Five Member Co...thesis Capacity , (PRWEB)...ading gene synthesis companies today announced agr...tocol to promote biosecurity in the gene synthesis...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4... today,announced the completion of a share capital...PCAS. PCAS, stake in Proteus now represents 32% of...e. Proceeds of this private,placement are to be us...AS,BIOSOLUTION businesses. PROTEUS ( http://www.p...izing, developing and producing new proteins and b...
..., a,clinical-stage biopharmaceutical company focus...f epidemic potential, announced today that the,U.S...ean Medicines Agency,(EMEA) independently reviewed...cies granted SQ109 orphan drug status for the trea...tro and in vivo activity against,drug-susceptible ...
...ng Facility Win Needed Medical Equipment by...RN, Pa., Oct. 22 Television medical dramas such a...hallenges in hospitals,across the country to milli...acking a cornerstone diagnostic technology - a mag...iven the opportunity to turn the cameras on,themse...
Other Biology Technology:PCAS : Tighter Links Between PCAS and Proteus 2Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis 2Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis 3American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 2American M.R.I.-DOL: Small Hospitals To Turn The Camera On Themselves In Unique National Contest 3Rabbit Anti-gp120/160(SIV/mac239) Polyclonal Antibody, Unconjugated from Immune Technology
Anti-Tropomyosin 4 Antibody, Unconjugated from CHEMICON
MagneSil KF, Genomic System from Promega
BAKERBOND WP PEI(CH2CH2NH) 15\um Prep HPLC Column from J.T. Baker
Biology Products: